Oxytocin vaginal - Peptonic Medical

Drug Profile

Oxytocin vaginal - Peptonic Medical

Alternative Names: oxytocin gel; oxytocin topical; Vagitocin

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Peptonic Medical
  • Class Hormones; Oxytocics
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Atrophic vaginitis

Most Recent Events

  • 20 Sep 2017 Oxytocin vaginal is still in phase IIb trials for Atrophic vaginitis in Sweden (EudraCT2016-000158-36)
  • 17 May 2017 Interim efficacy data from the phase II trial in Atrophic vaginitis released by Peptonic Medical
  • 03 May 2017 Peptonic Medical completes a phase IIb trial in Atrophic vaginitis in Sweden (EudraCT2016-000158-36)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top